Holen Sie sich die Stockscreener-App
7.31
2.24%
0.16
Schlusskurs vom Vortag:
$7.15
Offen:
$7.25
24-Stunden-Volumen:
1.92M
Relative Volume:
1.12
Marktkapitalisierung:
$449.43M
Einnahmen:
$91.06M
Nettoeinkommen (Verlust:
$-503.14M
KGV:
-0.8713
EPS:
-8.39
Netto-Cashflow:
$-424.74M
1W Leistung:
+2.38%
1M Leistung:
+5.33%
6M Leistung:
-15.49%
1J Leistung:
-67.07%
1-Tages-Spanne:
$7.15
$7.55
1-Wochen-Bereich:
$7.00
$7.55
52-Wochen-Spanne:
$4.62
$23.22
Sage Therapeutics Inc Stock (SAGE) Company Profile
Firmenname
Sage Therapeutics Inc
Sektor
Branche
Telefon
617-299-8380
Adresse
55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA
Vergleichen Sie SAGE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SAGE
Sage Therapeutics Inc
|
7.31 | 449.43M | 91.06M | -503.14M | -424.74M | -8.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Sage Therapeutics Inc Stock (SAGE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-21 | Hochstufung | RBC Capital Mkts | Underperform → Sector Perform |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-10-04 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-07-30 | Herabstufung | TD Cowen | Buy → Hold |
| 2024-07-25 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-05-29 | Eingeleitet | Citigroup | Sell |
| 2024-05-29 | Eingeleitet | Robert W. Baird | Neutral |
| 2024-04-17 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Hold |
| 2023-08-08 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2023-08-08 | Herabstufung | Goldman | Buy → Neutral |
| 2023-08-08 | Herabstufung | Needham | Buy → Hold |
| 2023-08-07 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-08-07 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-08-07 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-08-07 | Herabstufung | Stifel | Buy → Hold |
| 2023-08-07 | Herabstufung | Wedbush | Outperform → Neutral |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-03-13 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-01-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-11-01 | Eingeleitet | Loop Capital | Hold |
| 2022-03-31 | Eingeleitet | Berenberg | Hold |
| 2021-11-02 | Hochstufung | Guggenheim | Neutral → Buy |
| 2021-10-19 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2021-10-07 | Herabstufung | Jefferies | Buy → Hold |
| 2021-09-23 | Eingeleitet | Needham | Buy |
| 2021-06-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-04-07 | Eingeleitet | Piper Sandler | Overweight |
| 2021-02-26 | Herabstufung | Mizuho | Buy → Neutral |
| 2021-02-25 | Bestätigt | H.C. Wainwright | Neutral |
| 2021-02-02 | Fortgesetzt | Raymond James | Mkt Perform |
| 2021-01-22 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2021-01-04 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-12-04 | Hochstufung | Mizuho | Neutral → Buy |
| 2020-12-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-11-16 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-11-06 | Bestätigt | H.C. Wainwright | Neutral |
| 2020-09-11 | Hochstufung | Wedbush | Neutral → Outperform |
| 2020-08-10 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2020-05-08 | Herabstufung | Wedbush | Outperform → Neutral |
| 2020-04-08 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-03-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-06 | Eingeleitet | Citigroup | Buy |
| 2020-02-28 | Bestätigt | H.C. Wainwright | Neutral |
| 2020-02-06 | Eingeleitet | Mizuho | Neutral |
| 2019-12-06 | Bestätigt | RBC Capital Mkts | Outperform |
| 2019-12-05 | Bestätigt | Guggenheim | Buy |
| 2019-12-05 | Herabstufung | SunTrust | Buy → Hold |
| 2019-10-30 | Eingeleitet | H.C. Wainwright | Neutral |
| 2019-05-23 | Eingeleitet | Wedbush | Outperform |
| 2019-04-25 | Eingeleitet | Jefferies | Buy |
| 2018-12-14 | Eingeleitet | Wolfe Research | Outperform |
| 2018-10-11 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Sage Therapeutics Inc Aktie (SAGE) Neueste Nachrichten
Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
SAGE STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Sage Therapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Sage Therapeutics, Inc. (NASDAQ:SAGE) Sees Large Decline in Short Interest - MarketBeat
Analysts Offer Predictions for SAGE Q3 Earnings - MarketBeat
Sage Therapeutics (NASDAQ:SAGE) Issues Quarterly Earnings Results - MarketBeat
Wedbush Reiterates "Neutral" Rating for Sage Therapeutics (NASDAQ:SAGE) - MarketBeat
SAGE Therapeutics Faces Legal Challenges: Potential Impact on Financial Stability and Growth - MSN
Sage Therapeutics, Inc. (SAGE) Reports Q4 Loss, Lags Revenue Estimates - MSN
Q1 Earnings Forecast for SAGE Issued By Leerink Partnrs - MarketBeat
Scotiabank Cuts Sage Therapeutics (NASDAQ:SAGE) Price Target to $12.00 - MarketBeat
Sage Therapeutics (NASDAQ:SAGE) Price Target Cut to $8.00 by Analysts at Canaccord Genuity Group - MarketBeat
Sage Therapeutics (NASDAQ:SAGE) Receives Neutral Rating from HC Wainwright - MarketBeat
Needham & Company LLC Reaffirms "Hold" Rating for Sage Therapeutics (NASDAQ:SAGE) - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sage Therapeutics, Inc. (SAGE) And Encourages Shareholders to Reach Out - Markets Insider
Lifshitz Law PLLC Investigates Potential Securities Violations: Sage, SMCI, ZoomInfo & GitLab Under Scrutiny - HPBL
Sage Therapeutics (NASDAQ:SAGE) Earns “Hold” Rating from Needham & Company LLC - Defense World
Sage Therapeutics (NASDAQ:SAGE) Earns “Neutral” Rating from HC Wainwright - Defense World
What is Leerink Partnrs’ Estimate for SAGE Q1 Earnings? - Defense World
SAGE INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Sage Therapeutics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sage Therapeutics, Inc. (SAGE) and Encourages Shareholders to Learn More About the Investigation - Markets Insider
Sage Therapeutics price target lowered to $12 from $14 at Scotiabank - Yahoo Finance
Sage Therapeutics, Inc. (NASDAQ:SAGE) Q4 2024 Earnings Call Transcript - Insider Monkey
Sage Therapeutics' Q4 Earnings Miss Mark, Revenues Plunge Y/Y - MSN
Sage Therapeutics (SAGE) to Release Earnings on Tuesday - MarketBeat
(SAGE) Technical Data - Stock Traders Daily
SAGE Therapeutics’ Earnings Call: ZURZUVAE’s Success Amid Challenges - TipRanks
Sage Therapeutics (NASDAQ:SAGE) Releases Quarterly Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat
Canaccord cuts Sage Therapeutics price target to $8, holds rating - MSN
Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - Markets Insider
A Glimpse Into The Expert Outlook On Sage Therapeutics Through 7 Analysts - Benzinga
Canaccord cuts Sage Therapeutics price target to $8, holds rating By Investing.com - Investing.com South Africa
Hold Rating on SAGE Therapeutics Amid Underwhelming Sales and Strategic Uncertainties - TipRanks
Sage Therapeutics Inc (SAGE) Q4 2024 Earnings Call Highlights: S - GuruFocus.com
SG Americas Securities LLC Raises Holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World
Cambridge Biopharma Firm Sage Therapeutics Sues Partner Biogen After Buyout Offer - Harvard Crimson
Sage Therapeutics Inc (SAGE) Q4 2024 Earnings Call Highlights: Strong Prescription Growth Amid ... - Yahoo Finance
Sage Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
Sage Therapeutics Inc (SAGE) Q4 2024 Earnings Call Highlights: Strong Prescription Growth Amid ... By GuruFocus - Investing.com Canada
Sage Therapeutics Reports Strong 2024 Performance - TipRanks
Sage brushes off 'strategic alternatives' questions during earnings call - The Business Journals
Sage Therapeutics Inc. (SAGE) reports earnings - Quartz
SAGE Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
SAGE Therapeutics earnings missed by $0.06, revenue fell short of estimates - Investing.com
Bronstein, Gewirtz & Grossman, LLC Encourages Sage Therapeutics, Inc. (SAGE) Shareholders to Inquire about Securities Investigation - Markets Insider
Sage Therapeutics, Inc. SEC 10-K Report - TradingView
Sage Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Highlights Pipeline and Business Updates - Business Wire
Analysts Set Sage Therapeutics, Inc. (NASDAQ:SAGE) Price Target at $10.53 - MarketBeat
Finanzdaten der Sage Therapeutics Inc-Aktie (SAGE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.27%
3.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):